3/12
12:42 pm
fold
Pombiliti (Amicus Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, Forecasts [Yahoo! Finance]
Neutral
Report
Pombiliti (Amicus Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, Forecasts [Yahoo! Finance]
3/10
08:23 am
fold
Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis [Yahoo! Finance]
Low
Report
Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis [Yahoo! Finance]
3/10
08:23 am
fold
Chris Duke joins RBL LLC leadership team as Operating Partner [Yahoo! Finance]
Low
Report
Chris Duke joins RBL LLC leadership team as Operating Partner [Yahoo! Finance]
3/6
05:40 am
fold
How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin's Rare Disease Portfolio [Yahoo! Finance]
Low
Report
How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin's Rare Disease Portfolio [Yahoo! Finance]
3/5
12:28 pm
fold
Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus [Yahoo! Finance]
Low
Report
Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus [Yahoo! Finance]
2/23
09:44 am
fold
Amicus Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Amicus Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
2/20
04:01 pm
fold
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Low
Report
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
2/18
07:46 pm
fold
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections [Yahoo! Finance]
Low
Report
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections [Yahoo! Finance]
2/8
11:43 am
fold
Is Amicus Therapeutics (FOLD) Pricing Reflect Long Term Prospects In Rare Disease Treatments [Yahoo! Finance]
Low
Report
Is Amicus Therapeutics (FOLD) Pricing Reflect Long Term Prospects In Rare Disease Treatments [Yahoo! Finance]
2/8
04:28 am
fold
Assessing Amicus Therapeutics (FOLD) Valuation After Strong 3 Month And 1 Year Shareholder Returns [Yahoo! Finance]
Low
Report
Assessing Amicus Therapeutics (FOLD) Valuation After Strong 3 Month And 1 Year Shareholder Returns [Yahoo! Finance]
2/3
08:00 am
fold
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
Low
Report
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
2/1
06:25 am
fold
The Right Play On BioMarin Pharmaceuticals [Seeking Alpha]
Low
Report
The Right Play On BioMarin Pharmaceuticals [Seeking Alpha]
1/28
07:29 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
1/23
07:37 am
fold
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
Low
Report
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
1/22
05:02 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating.
1/9
07:03 pm
fold
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum [Yahoo! Finance]
Low
Report
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum [Yahoo! Finance]
1/9
04:31 am
fold
Is Amicus Therapeutics (FOLD) Pricing Reflect Recent 45% Surge And DCF Upside Potential [Yahoo! Finance]
Low
Report
Is Amicus Therapeutics (FOLD) Pricing Reflect Recent 45% Surge And DCF Upside Potential [Yahoo! Finance]
1/8
12:49 pm
fold
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights
1/6
07:25 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Guggenheim from a "strong-buy" rating to a "hold" rating.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Guggenheim from a "strong-buy" rating to a "hold" rating.
12/29
08:00 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $14.50 price target on the stock.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $14.50 price target on the stock.
12/26
03:28 pm
fold
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
Low
Report
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
12/24
10:32 pm
fold
Assessing Amicus Therapeutics (FOLD) Valuation After Its Recent Share Price Rally [Yahoo! Finance]
Neutral
Report
Assessing Amicus Therapeutics (FOLD) Valuation After Its Recent Share Price Rally [Yahoo! Finance]
12/23
02:53 pm
fold
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know [Yahoo! Finance]
Neutral
Report
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know [Yahoo! Finance]
12/23
07:06 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Citigroup Inc. from a "strong-buy" rating to a "hold" rating.
Neutral
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Citigroup Inc. from a "strong-buy" rating to a "hold" rating.
12/22
10:37 pm
fold
Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition [Yahoo! Finance]
Low
Report
Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition [Yahoo! Finance]